This material is private and confidential. It contains forward-looking projections and is provided for evaluation only — it is not an offer or solicitation of securities, and any investment is subject to definitive documentation and eligibility.
By entering, you confirm you are a qualified or sophisticated investor and agree to keep its contents confidential.
If you received this link in error, please close this page. © OROBORIUM 2026. All figures are illustrative projections, not guarantees.
A medical-tourism longevity & recovery clinic with luxury hospitality around it — not a resort with a doctor, but a clinic that earns from day one, with rooms and villas sold to property investors and a brand built to scale across Southeast Asia.
OROBORIUM is the first prototype of a new standard in human care and performance — a place where human fragility meets biological renaissance, where the rituals of the past fuse with the most advanced science of today.
Time slows. Cycles reset. The body begins again.
The affluent international patient faces a fragmented market: clinics with no hospitality, luxury wellness with no medical depth, recovery with disconnected care. OROBORIUM integrates the whole journey under one roof.
Advanced diagnostics, labs & longevity workup
IV, HBOT, regenerative & aesthetic protocols
Post-operative & restorative in-stay care
Helios AI membership & ongoing coaching
Medical services — not seasonal tourism — are the profit driver, profitable in Phase 1's first year.
Property investors fund the rooms & villas for a defined 12% yield — ring-fenced from the equity, so the SAFE never pays for construction.
A repeatable, integrated flagship designed to franchise and roll up across the region.
Global wellness economy, 2024 → 2029GWI 2025
Longevity & biohacking — IV therapy, cryotherapy, red-light, diagnostics — is called out by the Global Wellness Institute as a top-growth category. It's OROBORIUM's exact menu.
Medical tourism, 2024 → 2034 · ~14–21% CAGRPrecedence / GVR
Among the fastest-growing healthcare segments globally — and Indonesians alone spend ~$9.2B/yr on treatment abroad, demand the country is now repatriating.
Clinics with no hospitality. Luxury wellness with no medical depth. Recovery with disconnected care. No one owns the integrated longevity-recovery journey — the white space OROBORIUM is built for.
Indonesia opened medical practice to foreign specialists & subspecialists nationwide (Health Law 17/2023 + Gov. Reg. 28/2024) — practising within licensed facilities, with the competency evaluation waived for those with 5+ years' experience at recognised institutions. A door that was closed is now open.
The government's flagship Sanur Health SEZ and the 255-bed Bali International Hospital (opened 2025, inaugurated by President Prabowo) prove the medical-tourism thesis is national policy, not a bet. OROBORIUM sits in the Kura Kura SEZ — a 498-ha zone under master developer BTID — with its own SEZ incentives and a curated luxury setting.
Our advisors pushed us to separate fact from plan. So we do — openly. Honesty here is the point, not a disclaimer.
A small, fast, profitable clinic generates cash, customers and credibility — exactly the proof point most early-stage Bali projects never have — while the flagship is raised and built behind it.
A retrofit of a rented building in a Seminyak/Canggu demand hub. Fast, low-capital, profitable in year one.
Land-first, then a monumental clinic + amenities, raised and built while Phase 1 earns.
Seed (SAFE) + first SPV pre-sales; entities incorporated, land secured.
Lean clinic opens, earning & building the patient base.
Kura Kura facility comes online at 20 keys.
Built out to 26 keys; platform & franchise path.
Treatments, amenity passes & outpatient visits. Year-round, forward-booked medical demand — not seasonal tourism.
Diligence: $300 in-stay clinic spend / occupied room-night + 60 outpatient visits/mo @ $300, ramping to 1.2× by Year 5.
Room income across 26 keys at 58%→80% occupancy. This is what pays the property investors' 12%.
Diligence: blended ~$166/night across Solo→Family Villa; Year-3 room income covers yield owed 1.3×.
Membership ($9.99 basic / $49 clinical), on-site F&B and a meal-delivery line for Bali's fitness crowd.
Diligence: licensed arm's-length from Ateliersavant (flat $24K + 15% of app revenue) — fully disclosed related party.
Surface figures below; flip “Show the numbers” in the nav for the consolidated model, margins and the full 5-year build.
Consolidated EBITDA, 2027→2031
Seed (SAFE) MOIC / IRR · 5-yr base
Blended operating EBITDA margin
Phase-1 clinic payback
| USD | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|
| Total operating revenue | $1.0M | $5.0M | $6.3M | $7.3M | $8.3M |
| — Phase 1 clinic | $1.0M | $2.0M | $2.4M | $2.5M | $2.6M |
| — Phase 2 flagship (opens 2028) | — | $3.0M | $3.9M | $4.8M | $5.6M |
| Operating EBITDA — Phase 1 | $0.31M | $0.84M | $1.12M | $1.18M | $1.23M |
| Operating EBITDA — Phase 2 (to equity) | — | $0.28M | $0.89M | $1.46M | $1.87M |
| Consolidated EBITDA (profit to equity) | $0.31M | $1.12M | $2.01M | $2.64M | $3.11M |
Revenue vs. EBITDA: the top row is gross revenue ($1.0M → $8.3M); EBITDA is profit after all operating costs, COGS and the property-investor distribution — so it's naturally lower. The headline chart above plots EBITDA, which is what flows to equity.
Clean SAFE: $3.5M at a $12M post-money cap (≈29%). Property pre-sales (SPV) fund the rooms separately and are non-dilutive, so the SAFE never fronts construction. Base-case return ≈19% IRR / 2.4× MOIC over 5 years (sensitivity: ~14% / 1.9× at a 5× exit · ~17% / 2.1× at 6×). A €40K (~$43K) cheque returns ~$103K over 5 years. Upside beyond this — Phase 3 / franchise — is unmodelled. Assumes SPV pre-sales + optional ~$2M construction debt fund the rooms; all figures recomputed from Financial Model v7.
Use the “I'm a…” selector at the top — it highlights the path built for you. Equity buys the platform's growth; the SPV buys a yielding asset.
≈19% IRR · 5-yr base · uncapped upside
8% preferred + up to 4% performance
Physician advocacy, performance-vested
As qualifying PT PMA shares
Diligence: % of company = cheque ÷ $12.0M post-money cap (proposed — to confirm with counsel/lead). Seed cash-back applies the 2.4× base-case MOIC for the $3.5M SAFE (≈19% IRR; sensitivity 1.9–2.4× across a 5–7× exit). The SAFE never fronts construction — the SPV property pre-sales fund the rooms separately. SPV figure applies the 12% target yield.
A qualifying foreign shareholder in OROBORIUM's Indonesian PT PMA — holding ≥ IDR 1.125bn (~$70K) in personal shares and registered as a Director or Commissioner — can hold an Investor KITAS (1–2 years, renewable), with the right to live in Indonesia and run their own business, no separate work permit.
Immigration rules change — confirm specifics with a licensed advisor before relying on them.
Owns the brand, clinical protocols & AI platform. Where seed equity sits.
Licences, staff, land lease/HGB. ~25% effective tax; SEZ holiday = upside.
Each room/villa's income rights — asset-backed, senior to equity.
Diligence: founders 70% committed / ~57% fully-diluted; seed ~29–30%; physician pool ≤8% (performance-vested, self-financing); Dr Durand ≤5% (capped, co-branded menu only); GA = service contract, no equity. The physician pool dilutes all holders pro-rata.
OROBORIUM licenses the Helios AI app from Ateliersavant (founder-owned), structured arm's-length — a modest flat fee plus a revenue share — fully disclosed as a related-party item so outside investors can see value isn't being quietly moved out of the company.
Tax: PT PMA pays ~22% Indonesian CIT + ~5% treaty WHT to HK; HK does not tax foreign-sourced dividends. SEZ tax holiday modelled conservatively at zero benefit.
French entrepreneur, strategist and global designer. Early bionic-prosthesis research referenced by DARPA; client work spanning Nike to the White House, shown in international museums and design biennales. Now leads OROBORIUM, merging design with regenerative medicine.
Founder of Bali Luxe Medical and one of Australia's leading skin & body clinics; ex-KPMG in finance & technology. 2+ years running post-surgery recovery across Bali, with partnerships at every major hospital and a year of forward bookings already on the books.
Mathematics & physics background; helped merge two of Russia's national telecom operators, then led development and management of major Bali hospitality properties. Brings construction oversight, operations and guest-experience design.
Swiss- & French-licensed longevity MD, 28+ years across clinical operations, strategy and C-level healthcare leadership. Pioneer of "systemic longevity" frameworks that turn buildings into preventive-care ecosystems. Co-branded protocols & Scientific Advisory Circle.
⚠︎ Photography in production. Roster to be confirmed for this audience (the bios are drawn from the Rev009 deck). OROBORIUM is in active dialogue with additional doctors, scientists and industry experts regarding their involvement.
Close the $3.5M SAFE; incorporate the HK HoldCo + Indonesian PT PMA; open the first SPV pre-sales.
Agree Kura Kura terms with BTID and pay the securing deposit on the 25-year lease — land locked before build.
Retrofit the Seminyak/Canggu clinic, integrate Sherrie's operating post-op business, and report first real revenue.
Formalise post-op & referral agreements with Bali hospitals (BIH, BIMC, Puriva) and onboard founding physician advocates.
⚠︎ Proposed by Claude from the model & plan — Darius to confirm the exact targets and dates before fund distribution.
| Risk | Mitigation |
|---|---|
| Land terms & securing the lease (BTID) | Land-first funding; deal not closed until tenure ≥25 yrs is confirmed. |
| Licensing / credentialing timing (gates Phase-1 opening) | Local licensed doctors deliver from day one; foreign specialists credentialed in over time within a licensed facility. |
| Construction cost / time on Phase 2 | Monumental design is the heaviest cost lever; value-engineered & staged; Phase 1 earns meanwhile. |
| Slower ramp / occupancy | Preferred yield sized to conservative occupancy; year-round medical demand, not seasonal tourism. |
| Key-person dependence | Brand & protocols owned by HoldCo; Dr Durand capped & performance-based. |
| Execution complexity (clinic + hospitality + property) | Phase 1's small, fast footprint is itself the primary de-risking step. |
Honest answers — seed, property, strategic, visa, clinic, structure. Pick a topic.
This briefing is the surface. The full model, cap table, legal structure and data room come in a call with me and the team — request access below.
| Use | $ | % |
|---|---|---|
| Land — secure (deposit + prepaid) | $540K | 15% |
| Phase-1 lean clinic | $600K | 17% |
| Phase-2 shared clinic core (equity) | $1,400K | 40% |
| Entities, licensing, legal | $260K | 8% |
| Marketing & pre-opening | $200K | 6% |
| Working capital + contingency | $500K | 14% |
| Total | $3,500K | 100% |
The SPV property pre-sales (separate, ~$6M) fund the rooms/villas; this SAFE funds the platform's permanent equity. Data-room link provided on access.